Hepatic neuregulin 4 signaling defines an endocrine checkpoint for steatosis-to-NASH progression

Liang Guo, … , Weiping Zou, Jiandie D. Lin


Nonalcoholic steatohepatitis (NASH) is characterized by progressive liver injury, inflammation, and fibrosis; however, the mechanisms that govern the transition from hepatic steatosis, which is relatively benign, to NASH remain poorly defined. Neuregulin 4 (Nrg4) is an adipose tissue–enriched endocrine factor that elicits beneficial metabolic effects in obesity. Here, we show that Nrg4 is a key component of an endocrine checkpoint that preserves hepatocyte health and counters diet-induced NASH in mice. Nrg4 deficiency accelerated liver injury, fibrosis, inflammation, and cell death in a mouse model of NASH. In contrast, transgenic expression of Nrg4 in adipose tissue alleviated diet-induced NASH. Nrg4 attenuated hepatocyte death in a cell-autonomous manner by blocking ubiquitination and proteasomal degradation of c-FLIP<sub>L</sub>, a negative regulator of cell death. Adeno-associated virus–mediated (AAV-mediated) rescue of hepatic c-FLIP<sub>L</sub> expression in Nrg4-deficient mice functionally restored the brake for steatosis to NASH transition. Thus, hepatic Nrg4 signaling serves as an endocrine checkpoint for steatosis-to-NASH progression by activating a cytoprotective pathway to counter stress-induced liver injury.

Find the latest version:

http://jci.me/96324/pdf
Hepatic neuregulin 4 signaling defines an endocrine checkpoint for steatosis-to-NASH progression

Liang Guo,1 Peng Zhang,1 Zhimin Chen,1 Houjun Xia,2 Siming Li,1 Yanqiao Zhang,4 Sune Kobberup,5 Weiping Zou,2 and Jiandie D. Lin 1

1Life Sciences Institute and Department of Cell & Developmental Biology, University of Michigan Medical Center, Ann Arbor, Michigan, USA. 2Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, and Department of Biochemistry and Molecular Biology, Fudan University Shanghai Medical College, Shanghai, China. 3Department of Surgery, University of Michigan School of Medicine, Ann Arbor, Michigan, USA. 4Department of Integrative Medical Sciences, Northeast Ohio Medical University, Rootstown, Ohio, USA. 5Metabolic Disease Research, Novo Nordisk, Maaloev, Denmark.

Nonalcoholic steatohepatitis (NASH) is characterized by progressive liver injury, inflammation, and fibrosis; however, the mechanisms that govern the transition from hepatic steatosis, which is relatively benign, to NASH remain poorly defined. Neuregulin 4 (Nrg4) is an adipose tissue–enriched endocrine factor that elicits beneficial metabolic effects in obesity. Here, we show that Nrg4 is a key component of an endocrine checkpoint that preserves hepatocyte health and counters diet-induced NASH in mice. Nrg4 deficiency accelerated liver injury, fibrosis, inflammation, and cell death in a mouse model of NASH.

Introduction
Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of liver disorders linked to metabolic syndrome, ranging from simple fatty liver to more severe nonalcoholic steatohepatitis (NASH) (1–3). It has been estimated that over a third of the adult population in the US develops fatty liver disease (4). Hepatic steatosis results from a combination of adipose tissue dysfunction and dysregulation of hepatic lipid metabolism in an insulin-resistant state. NASH is characterized by the presence of persistent liver injury, chronic inflammation, and liver fibrosis. The latter is a wound-healing response that is activated following liver injury and potentially reversible at early stages (4). The transition from relatively benign hepatic steatosis to NASH marks a critical step in NAFLD progression that has important clinical implications, particularly the risk for end-stage liver disease, such as cirrhosis and hepatocellular carcinoma (5, 6). Multiple pathogenic drivers have been implicated in NASH initiation and progression, including oxidative stress, mitochondrial dysfunction, lipotoxicity, and immune cell activation (7–10). Despite this, the physiological mechanisms that defend against NASH progression remain poorly defined.

Liver injury as a result of hepatocyte death is at the center of many chronic liver diseases. Clinical and animal model studies have demonstrated that hepatocyte death is an important driver of liver disease progression (11–13). Aberrantly elevated liver cell death is linked to activation of liver regeneration and wound repair program, resulting in persistent inflammation and liver fibrosis that increase risk for cirrhosis and liver cancer. Several forms of hepatocyte death have been observed in the liver, including apoptosis, necrosis, and necroptosis. Hepatocyte apoptosis is a well-recognized cell death pathway in NASH. Mice with genetic deletion of caspase 8 in hepatocytes exhibited attenuated liver injury, inflammation, and fibrosis following methionine/choline-deficient (MCD) diet feeding (14). Caspase inhibitors have been shown to be protective in animal models of NASH (15, 16). Necroptosis is programmed necrosis that incorporates features of both apoptosis and necrosis (17, 18). The execution of necroptosis requires receptor-interacting protein 3 (RIPK3) and its substrate, mixed lineage kinase domain-like protein (MLKL). Upon RIPK3 activation, MLKL undergoes phosphorylation, oligomerization, and translocation to the plasma membrane, leading to membrane permeabilization and cell death. Necroptosis releases intracellular danger-associated molecular patterns, such as high-mobility group B1 (HMGB1), that have potential to trigger robust inflammatory response (13, 19). RIPK3 deficiency attenuates liver injury, steatosis, inflammation, and fibrosis in an MCD diet–induced NASH mouse model, implicating necroptosis in the liver as a contributor to NASH (20, 21). As such, targeting hepatocyte cell death may provide an effective approach to alleviating or reversing NASH progression (22).

Neuregulin 4 (Nrg4) is a member of the EGF-like family of extracellular ligands that is abundantly expressed in adipose tissue (23–25). We previously demonstrated that Nrg4 binds to hepatocytes, activates ErbB3 and ErbB4 receptor tyrosine kinases, and attenuates hepatic lipogenic response (25). Nrg4 deficiency exacerbates, whereas its Tg expression protects mice from, diet-induced
metabolic disorders. Interestingly, plasma Nrg4 levels inversely correlated with metabolic syndrome and NAFLD in 2 recent studies (26, 27). Recent genome-wide association studies indicate that polymorphisms in the ERBB4 locus are associated with obesity, diabetes, and diabetic nephropathy (28–30), illustrating a potential contribution of the Nrg4/ErbB4 pathway to the pathogenesis of metabolic disorders. Despite this, whether Nrg4 signaling regulates the transition from hepatic steatosis to NASH has not been explored. Using a diet-induced NASH model, we uncovered an unexpected function of Nrg4 in protecting hepatocytes from stress-induced cell death and attenuating NASH in mice. Mechanistically, Nrg4 exerts its cytoprotective effects on hepatocytes through attenuating ubiquitination and proteasomal degradation of cellular FADD-like apoptosis regulator (CFLAR, referred to as c-FLIPL hereafter), a negative regulator of apoptotic and necroptotic cell death (31, 32). These observations establish hepatic Nrg4 signaling as an endothocrine checkpoint for steatosis-to-NASH progression and reveal a potential target for therapeutic intervention.

Results

Human and mouse NASH is linked to increased apoptosis and necroptosis in the liver. Hepatocyte death is at the center of the transition from relatively benign hepatic steatosis to NASH. The latter is characterized by persistent liver injury, chronic inflammation, and progressive liver fibrosis. Despite the prominent role of cell death in NASH pathogenesis, the physiological cues that preserve hepatocyte health and tissue homeostasis of the liver under metabolic stress conditions remain poorly understood. To address this, we first investigated the nature of hepatocyte death in human NASH patients and in a mouse model of diet-induced NASH. Compared with non-NASH individuals, the levels of cleaved caspase 3 (CASP3) and phosphorylated MLKL (p–MLKL–S538), molecular markers of apoptosis and necroptosis, respectively, were markedly elevated in liver biopsies from a cohort of NASH patients (33) (Figure 1A). The induction of cell death in NASH livers was associated with increased phosphorylation of JNK1/2 and reduced protein levels of c-FLIPL, an inhibitor of apoptotic and necroptotic cell death. Quantitative PCR (qPCR) gene-expression analysis indicated that mRNA expression of genes involved in inflammation and fibrosis was markedly increased in the liver from NASH patients (Figure 1B).

We next evaluated a recently described high-fat high-fructose diet (NASH diet) in inducing key aspects of NASH pathology in mice (34). We fed a cohort of WT C57BL/6J mice standard chow or NASH diet for approximately 20 weeks. NASH diet–fed mice developed obesity and severe hepatic steatosis (Figure 1C and Supplemental Figure 1, A and B; supplemental material available online with this article; https://doi.org/10.1172/JCI96324DS1). Hepatic lipid droplet number and size were similar between 2 groups under chow-fed conditions (Supplemental Figure 2, A–D). Following NASH diet feeding, Nrg4-KO mice had slightly higher liver triacylglycerol (TAG) content than control (Figure 2A). While the number of lipid droplets in hepatocytes was comparable, lipid droplets were slightly larger in mice lacking Nrg4 (Supplemental Figure 2, E and F). The exacerbation of hepatic steatosis by Nrg4 deficiency was less marked compared with what was observed in mice fed HFD, which does not contain fructose and cholesterol. Plasma levels of ALT, AST, and HMGB1, the biomarkers of liver injury, were significantly elevated in Nrg4-KO mice following NASH feeding (Figure 2A). Nrg4-null mice exhibited more severe liver fibrosis, as revealed by Sirius red staining and measurements of liver hydroxyproline content (Figure 2, B and C). Nrg4 deficiency also resulted in increased abundance of F4/80-positive macrophages and TUNEL-positive cells. Immunoblotting analysis indicated that CASP3 and PARP cleavage, MLKL phosphorylation, and JNK activation were strongly increased in Nrg4-KO mouse livers (Figure 2D). In contrast, c-FLIPL protein levels were markedly reduced by Nrg4 deficiency.

Transcriptional profiling analysis identified 2 clusters of upregulated and downregulated genes in Nrg4-null mouse livers. Gene ontology analysis indicated that the upregulated genes are highly enriched for extracellular matrix, wound healing, and colla-
gen, whereas the downregulated cluster was enriched for genes involved in lipid metabolism (Figure 2E). Consistently, mRNA expression of genes involved in liver fibrosis, including Ccolla1, Acta2, Tgfb1, and Mmp13, and hepatic inflammation, including Tnfα, Il1b, Il12b, Nos2, Ccl2, Ccl5, and Adgre1 (F4/80), was significantly elevated in the livers from Nrg4-null mice (Figure 2F). These findings illustrate that Nrg4 deficiency worsened liver inflammation and fibrosis following NASH diet feeding. Th17 cells
Figure 2. Nrg4 deficiency exacerbates diet-induced NASH in mice. Control WT (n = 12, black) and Nrg4-KO (n = 12, gray) male mice were fed NASH diet for 20 weeks, starting at 3 months of age. (A) Plasma ALT, AST, and HMGB1 levels and liver TAG content. Data represent mean ± SEM. *P < 0.05; **P < 0.01, 2-tailed unpaired Student’s t test. (B) H&E, sirius red, F4/80 immunofluorescence, and TUNEL staining of liver sections. Scale bars: 100 μm. (C) Quantification of sirius red, F4/80, and TUNEL staining images and liver hydroxyproline content. Data represent mean ± SEM. **P < 0.01; ***P < 0.001, 2-tailed unpaired Student’s t test. (D) Immunoblots of total liver lysates from NASH diet–fed mice. (E) Heatmap representation of hepatic genes up- or downregulated by Nrg4 deficiency following NASH diet feeding (top). Enrichment of biological processes in these 2 clusters (bottom). (F) qPCR analysis of hepatic gene expression. Data represent mean ± SEM. *P < 0.05; **P < 0.01, 2-tailed unpaired Student’s t test. (G) Flow cytometry analysis of liver CD4+ T cells. Results are expressed as percentage (%) of IL-17+, TNF-α+, RORγt+, and FOXP3+ cells in total liver CD4+ T cells. Data represent mean ± SEM. *P < 0.05; **P < 0.01, 2-tailed unpaired Student’s t test.
and IL-17 have recently been implicated in promoting steatohepatitis and liver fibrosis (35). Flow cytometry analysis indicated that the populations of Th17 cells and RORγt+CD4+ T cells were significantly increased in Nrg4-null mouse livers (Figure 2G). These results suggest that increased Th17 cell infiltration and IL-17 signaling may contribute to the exacerbation of NASH phenotypes in Nrg4-null mice. Together, these data demonstrate that Nrg4 signaling protects mice from diet-induced NASH and that its deficiency exacerbates key pathogenic events of NASH.

**Tg restoration of the Nrg4 endocrine axis protects mice from NASH.** Having established that Nrg4 deficiency is causally linked to NASH, we next explored whether Tg restoration of Nrg4 signaling is sufficient to ameliorate diet-induced NASH in mice. We fed WT and fat-specific Nrg4-Tg mice standard chow or NASH diet for approximately 20 weeks. Hepatic steatosis and fibrosis, plasma ALT and AST, and mRNA expression of genes involved in liver fibrosis and inflammation were similar between 2 groups following chow feeding (Supplemental Figure 3, A-D). Following NASH diet feeding, Nrg4-Tg mice had moderately lower liver fat content (Figure 3A), slightly smaller lipid droplets in hepatocytes (Supplemental Figure 3, E and F), and significantly lower plasma ALT, AST, and HMGB1 levels (Figure 3A), suggesting that Tg expression of Nrg4 may improve NASH diet-induced liver injury. In support of this, liver fibrosis and hydroxyproline content were significantly reduced in Tg mouse livers (Figure 3, B and C). Immunofluorescence staining revealed that the abundance of F4/80+ macrophages and TUNEL-positive cells was reduced in Tg mice, indicative of attenuated liver inflammation and hepatocyte death. Consistently, mRNA expression of genes involved in hepatic inflammation and fibrosis was significantly downregulated in Nrg4-Tg mouse livers, accompanied by reduced population of Th17 cells and RORγt+CD4+ T cells (Figure 3, D and E). Nrg4-Tg mouse livers exhibited reduced CASP3 and PARP cleavage and MLKL phosphorylation (Figure 3F). The levels of phosphorylated JNK were lower in Tg livers, whereas c-FLIP L protein levels were elevated in the livers of Nrg4-Tg mice. The strikingly opposite effects of Nrg4 deficiency and Tg expression on diet-induced NASH illustrate a crucial role of Nrg4 in serving as an endocrine checkpoint for steatosis-to-NASH progression. Given that Nrg4 manipulations only moderately affect the severity of hepatic steatosis, our results suggest that Nrg4 may exert cytoprotective functions on hepatocytes independently of its regulation of lipid metabolism.

**Nrg4 signaling protects hepatocytes from stress-induced cell death through c-FLIP.** Hepatocyte death is at the center of NASH initiation and progression, triggering chronic inflammation and fibrosis in the liver. The findings that liver injury was increased in Nrg4-null mice while attenuated in Nrg4-Tg mice prompted us to investigate whether Nrg4 directly modulates hepatocyte death. Previous work has demonstrated that liver expresses all ErbB receptors except ErbB2 (36). However, ErbB4 expression in primary hepatocyte culture is relatively low. We reconstituted Nrg4/ErbB4 signaling by transducing primary hepatocytes with a recombinant adenoviral vector expressing ErbB4, as previously described (25). As expected, recombinant Nrg4 dose-dependently stimulated ErbB4 receptor tyrosine phosphorylation and AKT phosphorylation in transduced primary hepatocytes (Figure 4A). NASH-associated hepatocyte death results from an array of stress signals, most notably lipotoxicity and proinflammatory cytokines. Previous studies have demonstrated that treatments of primary hepatocytes with a combination of palmitic acid (PA) and TNF-α (PA/TNF-α) robustly triggered cell death that mimics NASH-induced liver injury (21, 37). To investigate whether Nrg4 plays a direct role in the regulation of hepatocyte death, we treated primary hepatocytes transduced with GFP or ErbB4 adenovirus with PA/TNF-α. As expected, PA/TNF-α treatment increased CASP3 and PARP cleavage and MLKL phosphorylation in hepatocytes transduced with Ad-GFP, indicative of induction of apoptotic and necroptotic cell death in response to PA and TNF-α (Figure 4B). Nrg4 treatment strongly attenuated cell death markers in primary hepatocytes expressing ErbB4. We measured the release of lactate dehydrogenase (LDH) into culture media as an indicator of hepatocyte death (38). LDH release by primary hepatocytes was markedly increased in response to PA/TNF-α treatment (Figure 4C). Activation of Nrg4 signaling strongly attenuated LDH release induced by PA/TNF-α. Further, flow cytometry analysis using annexin V and propidium iodide (PI) staining indicated that PA/TNF-α treatment increased the frequency of apoptotic (annexin V positive and PI negative) and dead (double positive) cells, which was significantly alleviated by Nrg4 (Figure 4, D and E). Similar protective effects of Nrg4 were also observed in transduced Hepa 1 hepatoma cells stably expressing ErbB4 (Figure 4, F and G, and Supplemental Figure 4, A–C).

c-FLIP L is a cell death inhibitory protein that has been shown to suppress both apoptosis and necroptosis and protect against liver injury in mice (39–41). As shown above, c-FLIP L protein level was reduced in Nrg4-null mouse livers, but elevated by Nrg4-Tg expression in adipose tissue. These observations suggest that c-FLIP L may be a downstream effector of Nrg4 that links Nrg4/ErbB4 signaling to hepatocyte death. Interestingly, c-FLIP L mRNA expression in Nrg4-null and -Tg mouse livers remained largely unchanged (Figure 2F and Figure 3D), suggesting that Nrg4 may regulate c-FLIP L protein levels through posttranslational mechanisms. In support of this, we found that endogenous c-FLIP L protein levels were reduced in hepatoma cells in response to PA/TNF-α treatment without affecting c-FLIP L mRNA levels (Figure 5A and Supplemental Figure 5A). Nrg4 treatment stimulated AKT phosphorylation, attenuated JNK phosphorylation, and nearly completely blocked the decrease of c-FLIP L protein expression by PA/TNF-α treatment. Cycloheximide (CHX) chase studies indicated that Nrg4 increased the half-life of c-FLIP L in hepatoma cells (Figure 5B). Accordingly, the proteasome inhibitor MG132 blocked PA/TNF-α-induced decrease of c-FLIP L (Figure 5C), consistent with a posttranslational mechanism of regulation.

We next performed studies in Hepa 1 cells stably expressing ErbB4 using a retroviral vector to dissect the role of c-FLIP L in mediating the cytoprotective activity of Nrg4. Interestingly, c-FLIP L protein level was markedly reduced, whereas CASP3 cleavage and MLKL phosphorylation were stimulated, in response to PA/TNF-α treatment (Figure 5D). The effects of PA/TNF-α on c-FLIP L protein level and cell death markers were partially reversed by Nrg4 treatment. Further, adenovirus-mediated expression of c-FLIP L greatly diminished PA/TNF-α-induced apoptotic and necroptotic cell death. These results were confirmed by LDH release and flow cytometry analyses (Figure 5, E and F, and Supplemental Figure
We did not observe further improvement of cell viability by Nrg4 in c-FLIP L–overexpressing hepatoma cells, suggesting that the protective effects of Nrg4 are largely mediated by its induction of c-FLIP L protein expression.

Nrg4 attenuates ubiquitination and proteasomal degradation of c-FLIP L. We performed ubiquitination assay to determine whether PA/TNF-α and Nrg4 play an antagonistic role in c-FLIP L ubiquitination. As shown in Figure 6A, PA/TNF-α treatment induced robust polyubiquitination of c-FLIP L that was largely reversed by Nrg4 treatment. We next determined whether AKT activation by Nrg4 is required for its regulation of c-FLIP L protein stability. We performed PA/TNF-α and Nrg4 treatments without or with AKTi, a specific AKT inhibitor. The ability of Nrg4 to attenuate c-FLIP L ubiquitination in response to PA/TNF-α treatment was greatly diminished in the presence of AKTi (Figure 6B). As a result, Nrg4 failed to stabilize c-FLIP L protein and suppress PA/TNF-α–induced cell death, leading to improved cell viability (Figure 6, B–D). On the contrary, inhibition of JNK kinase activity blocked the induction of c-FLIP L ubiquitination by PA/TNF-α treatment, leading to improved cell viability (Figure 6, E and F). Nrg4 treatment did not further decrease c-FLIP L ubiquitination. As such, Nrg4 exerts opposing
effects on the AKT and JNK signaling pathways to regulate c-FLIPL ubiquitination and proteasomal degradation in response to PA/TNF-α. Further, the reciprocal regulation of c-FLIP L protein levels in Nrg4-KO and -Tg mouse livers likely reflects cell-autonomous action of Nrg4 in hepatocytes.

Previous work has identified Itchy E3 ubiquitin protein ligase (Itch) as a JNK-regulated E3 ubiquitin ligase for c-FLIP L (42). To investigate whether Itch is required for ubiquitination and proteasomal degradation of c-FLIP L in response to PA/TNF-α, we knocked down Itch in Hepa 1 cells using 2 independent siRNA pools against Itch. Surprisingly, siRNA knockdown of Itch did not appear to affect c-FLIPL ubiquitination and degradation and PA/TNF-α–induced cell death (Supplemental Figure 5, B and C). These results suggest that it is unlikely that Itch is the E3 ubiquitin ligase responsible for PA/TNF-α–induced c-FLIP L ubiquitination.

Restoration of hepatic c-FLIP L protein expression will improve diet-induced NASH in mice due to Nrg4 deficiency. To test this, we generated a c-FLIP L expression vector using adeno-associated virus (AAV) type 8 under the control of the liver-specific thyroid hormone-binding globulin (Tbg) promoter. Tail vein injection of AAV–c-FLIP L elevated c-FLIP L expression specifically in the liver, but not other tissues, such as adipose tissue, spleen, and lung (Supplemental Figure 6A). We fed WT and Nrg4-null mice NASH diet for 8 weeks and transduced these mice with control AAV-GFP or AAV–c-FLIP L virus. Four treatment groups were obtained: WT mice injected with AAV-GFP (WT/GFP) or AAV–c-FLIP L (WT/c-FLIP L) and Nrg4-KO mice injected with AAV-GFP (Nrg4 KO/GFP) or AAV–c-FLIP L (Nrg4 KO/c-FLIP L). We examined NASH features in transduced mice following an additional 12 weeks of NASH diet feeding. Similar to what occurred in the studies shown in Figure 2, Nrg4 deficiency accelerated diet-induced NASH in mice. Compared with WT/GFP, Nrg4-KO/GFP mice had higher plasma ALT, AST, and HMGB1 levels, developed more severe liver fibrosis, and exhibited increased presence of apoptotic cells (Figure 7, A–C). While AAV-mediated overexpression of c-FLIP L moderately improved
ing apoptosis and necroptosis, exert strong effects on the progression of both acute and chronic liver disease. Despite this, the signaling mechanisms that counter pathophysiological insults and preserve hepatocyte health in NASH remain poorly understood. In this study, we uncovered an adipose-hepatic endocrine axis that functions as a checkpoint for diet-induced NASH in mice. Nrg4 protects hepatocytes from apoptosis and necroptosis triggered by metabolic and inflammatory stress by attenuating ubiquitination and proteasomal degradation of c-FLIPL (Figure 8C). As such, activation of Nrg4-mediated endocrine signaling may provide a new therapeutic avenue for halting and/or reversing NASH pathogenesis in humans.

The observation that Nrg4, a fat-derived endocrine factor, plays a direct role in cell death signaling in hepatocytes came somewhat as a surprise. We previously demonstrated that Nrg4 exerts pleiotropic effects on hepatic and systemic energy metabolism in diet-induced obesity (25). However, HFD used in the previous studies was inadequate in triggering liver injury and NASH. Here, we used a high-fat, high-fructose diet that elicits key aspects of human NASH pathologies in mice (34). Notably, NASH diet-induced apoptotic and necrotic cell death in mouse liver was linked to downregulation of c-FLIPL, a prosurvival factor, closely resembling the observations in NASH patient livers. Several lines of evidence support the pathophysiological significance of Nrg4 in gating the transition from hepatic steatosis to NASH. Nrg4-null mice developed more severe liver injury upon NASH diet feeding, as shown by elevated plasma levels of ALT, AST, and HMGB1. Liver cell death and inflammation were increased in mice lacking Nrg4, leading to more severe liver fibrosis. In contrast, fat-specific Tg Nrg4 expression restored Nrg4 deficiency and ameliorated the severity of diet-induced NASH in mice. Activation of Nrg4 signaling attenuated apoptotic and necrotic cell death in hepatocytes in a cell-autonomous manner, illustrating a direct role of Nrg4 in preserving liver health under stress conditions.

Discussion
A hallmark of NASH is the presence of persistent liver injury as a result of increased hepatocyte death, which serves as a pathogenic trigger for liver inflammation and fibrosis (13, 43). Genetic manipulations that impinge on the cell death pathways, including apoptosis and necroptosis, exert strong effects on the progression of both acute and chronic liver disease. Despite this, the signaling mechanisms that counter pathophysiological insults and preserve hepatocyte health in NASH remain poorly understood. In this study, we uncovered an adipose-hepatic endocrine axis that functions as a checkpoint for diet-induced NASH in mice. Nrg4 protects hepatocytes from apoptosis and necroptosis triggered by metabolic and inflammatory stress by attenuating ubiquitination and proteasomal degradation of c-FLIPL, (Figure 8C). As such, activation of Nrg4-mediated endocrine signaling may provide a new therapeutic avenue for halting and/or reversing NASH pathogenesis in humans.

The observation that Nrg4, a fat-derived endocrine factor, plays a direct role in cell death signaling in hepatocytes came somewhat as a surprise. We previously demonstrated that Nrg4 exerts pleiotropic effects on hepatic and systemic energy metabolism in diet-induced obesity (25). However, HFD used in the previous studies was inadequate in triggering liver injury and NASH. Here, we used a high-fat, high-fructose diet that elicits key aspects of human NASH pathologies in mice (34). Notably, NASH diet-induced apoptotic and necrototic cell death in mouse liver was linked to downregulation of c-FLIPL, a prosurvival factor, closely resembling the observations in NASH patient livers. Several lines of evidence support the pathophysiological significance of Nrg4 in gating the transition from hepatic steatosis to NASH. Nrg4-null mice developed more severe liver injury upon NASH diet feeding, as shown by elevated plasma levels of ALT, AST, and HMGB1. Liver cell death and inflammation were increased in mice lacking Nrg4, leading to more severe liver fibrosis. In contrast, fat-specific Tg Nrg4 expression restored Nrg4 deficiency and ameliorated the severity of diet-induced NASH in mice. Activation of Nrg4 signaling attenuated apoptotic and necrototic cell death in hepatocytes in a cell-autonomous manner, illustrating a direct role of Nrg4 in preserving liver health under stress conditions.

At the mechanistic level, Nrg4 engages the prosurvival factor c-FLIP{sub}L to attenuate stress-induced cell death in hepatoma cells. The following experiments were performed in Hepa1 cells stably expressing ErbB4. Cells were cultured in serum-free medium during treatment. (A) Immunoblots of total lysates from cells treated with PA/TNF-α in the absence or presence of 100 ng/ml Nrg4 for 6 hours. (B) Immunoblots of total lysates from cells treated with PA/TNF-α without or with 100 ng/ml Nrg4 and chased for different times in the presence of 2 μM CHX. (C) Immunoblots of total lysates from cells treated with PA/TNF-α without or with 100 ng/ml Nrg4 and chased for 6 hours in the presence of 10 μM MG132. (D) Immunoblots of total lysates from treated cells. Hepa1 cells stably expressing ErbB4 were transduced with Ad-GFP or Ad-c-FLIP{sub}L adenoviral vector. Transduced cells were treated with 100 μM PA for 2 hours followed by addition of 20 ng/ml TNF-α and 100 ng/ml Nrg4 for 20 hours. (E) LDH release by treated Hepa1 cells (20 hours treatment). Data represent mean ± SEM. **P < 0.01, 1-way ANOVA. (F) Flow cytometry analysis (20 hours treatment). Data represent mean ± SEM. **P < 0.01; ***P < 0.001, 1-way ANOVA.
Interestingly, Nrg4 appeared to predominantly affect the c-FLIP<sub>L</sub> isoform in the liver. c-FLIP<sub>L</sub> forms a heterodimer with procaspase 8 to inhibit its activation and suppress the activation of apoptosis and necroptosis. For example, c-FLIP<sub>L</sub> protects cells from Fas-induced cell death, involving both apoptosis and necroptosis (44), and the formation of cell death–inducing ripoptosome in response to Toll-like receptor 3 activation (45). Inactivation of c-FLIP<sub>L</sub> in mouse hepatocytes promotes liver injury triggered by death receptor agonists (39). A recent study demonstrated that AAV-mediated overexpression of c-FLIP<sub>L</sub> in the liver ameliorates NASH in mice and nonhuman primates (41), illustrating a crucial role of this factor in NASH. However, the physiological and pathophysiological cues that impinge on c-FLIP<sub>L</sub> remain largely unknown. Our current work uncovers adipose endocrine signaling via Nrg4 as a key regulator of c-FLIP<sub>L</sub> ubiquitination and proteasome-mediated degradation. Nrg4 strongly blunts JNK1/2 activation in hepatocytes in an AKT-dependent manner following PA/TNF-α treatment, leading to increased c-FLIP<sub>L</sub> protein stability. These results are consistent with previous work that demonstrates an important role for JNK in posttranslational regulation of c-FLIP<sub>L</sub> (42). Notably, restoration of hepatic c-FLIP<sub>L</sub> protein expression alleviated diet-induced NASH in Nrg4-null mice without affecting steatosis, suggesting that the Nrg4/c-FLIP<sub>L</sub> pathway exerts an independent effect on steatosis-to-NASH progression. Our work elucidates the molecular nature and pathophysiological significance of an endocrine checkpoint that regulates steatosis-to-NASH progression. Future work will further validate Nrg4-based therapeutic biologics for NASH treatment.

Figure 6. Nrg4 attenuates ubiquitination and proteasomal degradation of c-FLIP<sub>L</sub>. The following experiments were performed in Hepa 1 cells stably expressing ErbB4. Cells were cultured in serum-free medium during treatment. WCL, whole cell lysates. (A) Immunoblots of IP and whole cell lysates from Hepa 1 cells transfected with plasmids encoding HA-tagged c-FLIP<sub>L</sub> and Flag-tagged ubiquitin (Flag-Ub) and treated with PA/TNF-α without or with 100 ng/ml Nrg4 for 4 hours. (B) Immunoblots of IP and whole cell lysates from transfected Hepa 1 cells treated in the absence or presence of AKT kinase inhibitor (20 μM) for 4 hours. (C) Immunoblots of total lysates from cells treated with PA/TNF-α without or with 100 ng/ml Nrg4 and in the absence or presence of AKT inhibitor (20 μM) for 6 hours. (D) LDH release by Hepa 1 cells as treated for 20 hours. Data represent mean ± SEM. ***P < 0.001, 1-way ANOVA. (E) Immunoblots of IP and WCL from transfected Hepa 1 cells treated in the absence or presence of JNK1/2 kinase inhibitor (20 μM) for 4 hours. (F) LDH release by Hepa 1 cells as treated for 20 hours. Data represent mean ± SEM. ***P < 0.001, 1-way ANOVA.
same genotype to different treatments to minimize any potential bias. The investigators were not blinded to allocation during experiments and outcome assessment. We excluded mice that exhibited skin lesions due to fighting and growth retardation as a result of malocclusion.

Human studies. Human liver samples were obtained from the Liver Tissue Cell Distribution System at the University of Minnesota (Minneapolis, Minnesota, USA) (33). Both male and female individuals were included. The average ages for normal individuals and NASH patients were 55.8 and 52.5 years old, respectively. Individuals with an alcohol-drinking history (2 to 3 drinks/day) and liver cancer were excluded from the study.

Hepatocyte treatment and cell death studies. Primary hepatocytes were isolated as previously described by using collagenase type II from C57BL/6J mice (25). Hepatocytes were maintained in DMEM medium containing 10% bovine growth serum (BGS) at 37°C and 5% CO₂. Hepatocytes were infected with adenovirus on the same day as isolation. After a total of 20 weeks of NASH diet feeding, mice were sacrificed for analysis.

We did not predetermine sample size, but used group sizes typical for this type of work in the literature. We randomly assigned mice of the same genotype to different treatments to minimize any potential bias. The investigators were not blinded to allocation during experiments and outcome assessment. We excluded mice that exhibited skin lesions due to fighting and growth retardation as a result of malocclusion.

Figure 7. AAV-mediated restoration of hepatic c-FLIPL alleviates NASH phenotype in Nrg4-deficient mice. The following parameters were measured in WT and Nrg4-KO male mice fed NASH diet for a total of 20 weeks. AAV8-GFP and AAV8-c-FLIPL vectors were administered 8 weeks following the initiation of NASH feeding. WT/GFP group, n = 8; WT/c-FLIPL group, n = 7; Nrg4-KO/GFP group, n = 8; Nrg4 KO/c-FLIPL group, n = 7. (A) Plasma ALT, AST, and HMGB1 levels. Data represent mean ± SEM. *P < 0.05, **P < 0.01, WT/GFP vs. Nrg4-KO/GFP; *P < 0.05, **P < 0.01, ***P < 0.001, Nrg4-KO/GFP vs. Nrg4-KO/c-FLIPL, 1-way ANOVA. (B) H&E, sirius red, F4/80 immunofluorescence, and TUNEL staining of liver sections. Scale bars: 100 μm. (C) Quantification of sirius red, F4/80, and TUNEL staining images and liver hydroxyproline content. Data represent mean ± SEM. *P < 0.05, **P < 0.01, WT/GFP vs. Nrg4 KO/GFP; ***P < 0.01, ###P < 0.001, Nrg4 KO/GFP vs. Nrg4 KO/c-FLIPL, 1-way ANOVA.

Methods
Animal studies. Mice were housed under 12-hour light/12-hour dark cycles with free access to food and water. For chow feeding, mice were fed Teklad 5001 Laboratory Diet. For NASH diet feeding, mice were fed a diet containing 40% fat (of which 18% was trans fat), 22% fructose, and 2% cholesterol (D09100301, Research Diets Inc.) starting at 3 months of age. Nrg4-knockout mice and Nrg4-Tg mice have been described previously (25). Nrg4-KO mice were purchased from the Mutant Mice Regional Resource Center (MMRRC) at UCD and backcrossed for more than 10 generations to the C57BL/6J background. Nrg4-Tg mice on a C57BL/6J background were generated at the Transgenic Animal Model Core at the University of Michigan. For AAV8 transduction, AAV8-GFP or AAV8c-FLIPL (1 × 10¹² genome copies/mouse) was delivered by tail vein injection following 8 weeks of NASH diet feeding. After a total of 20 weeks of NASH diet feeding, mice were sacrificed for analysis.

We did not predetermine sample size, but used group sizes typical for this type of work in the literature. We randomly assigned mice of the same genotype to different treatments to minimize any potential bias. The investigators were not blinded to allocation during experiments and outcome assessment. We excluded mice that exhibited skin lesions due to fighting and growth retardation as a result of malocclusion.

Human studies. Human liver samples were obtained from the Liver Tissue Cell Distribution System at the University of Minnesota (Minneapolis, Minnesota, USA) (33). Both male and female individuals were included. The average ages for normal individuals and NASH patients were 55.8 and 52.5 years old, respectively. Individuals with an alcohol-drinking history (2 to 3 drinks/day) and liver cancer were excluded from the study.

Hepatocyte treatment and cell death studies. Primary hepatocytes were isolated as previously described by using collagenase type II from C57BL/6J mice (25). Hepatocytes were maintained in DMEM medium containing 10% bovine growth serum (BGS) at 37°C and 5% CO₂. Hepatocytes were infected with adenovirus on the same day as isolation. After 24 hours, cells were switched to serum-free DMEM for 12 hours
before PA, TNF-α, and/or Nrg4 treatment. Hepa 1 cells (ATCC, CRL-1830) were maintained in DMEM medium containing 10% BGS at 37°C and 5% CO₂. To establish a Hepa 1 cell line stably expressing ErbB4, Hepa 1 cells were infected with pBABE retroviral vector harboring the ErbB4 gene and screened with hygromycin (250 μg/ml final concentration) for at least 2 weeks. Hepa 1 cells were switched to serum-free DMEM for 12 hours before treatments with PA, TNF-α, AKT inhibitor (AKT Inhibitor VIII; Sigma-Aldrich, catalog A6730), JNK inhibitor (SP 600125; Sigma-Aldrich, catalog 474787), and Nrg4 (Novo Nordisk). To knock down Itch in Hepa 1 cells, siRNAs against Itch (catalog 4390771, ID: S68413 and S68414) and control siRNA (catalog 4390843) were purchased from Thermo Fisher Scientific. Lipofectamine RNAiMAX Transfection Reagent (catalog 13778030) was used for siRNA transfection. Cell death was evaluated using the LDH Cytotoxicity Colorimetric Assay Kit II (BioVision, K313-500). LDH values were normalized to maximum releasable LDH activity after cell lysis.

**Gene expression analysis.** Total RNA from adipose tissues was extracted using a commercial kit from Invitrogen. RNAs from other tissues was extracted using the TRizol method. For qPCR analysis, an equal amount of RNA was reverse-transcribed using MMLV-RT followed by qPCR reactions using SYBR green (Life Technologies). Relative abundance of mRNA was normalized to ribosomal protein 36B4. The primers for qPCR are listed in Supplemental Table 1.

For microarray study of liver gene expression, total liver RNA isolated from NASH diet-fed WT and Nrg4-KO mice was used to generate probes for Affymetrix Mouse Gene ST 2.1 array strips. Sample processing and data analyses were performed according to the manufacturer’s instructions. All original microarray data were deposited in the NCBI’s Gene Expression Omnibus database (GEO GSE99753).

**Immunoblotting analysis.** For total lysates, livers were homogenized in a lysis buffer containing 50 mM Tris (pH 7.5), 150 mM NaCl, 5 mM NaF, 25 mM β-glycerol phosphate, 1 mM sodium orthovanadate, 10% glycerol, 1% Triton X-100, 1 mM dithiothreitol (DTT), and freshly added protease inhibitors (Roche). Cells were harvested and homogenized with lysis buffer containing 2% sodium dodecyl sulfate (SDS), 50 mM Tris-HCl (pH 6.8), 10 mM DTT, 10% glycerol, 0.002% bromphenol blue, and freshly added protease inhibitors. For protein stability assays, cells were treated with CHX (Sigma-Aldrich) before harvest. Immunoblotting experiments were performed using specific antibodies. For immunoblots, antibodies against c-FLIP L (sc-5276) and HA-tag (sc-805) were from Santa Cruz Biotechnology Inc. Antibodies against caspase-3 (catalog 9661), PARP (catalog 9542), phospho-ErbB4 (Y1284) (catalog 4757), total ErbB4 (catalog 4795), phospho-STAT5 (Y694) (catalog 9359), total STAT5 (catalog 9363), and phospho-MLKL (S345) (catalog 91689) were from Cell Signaling Technology. Antibodies against Flag-tag (F1904) and Tubulin (T6199) were from Sigma-Aldrich.
Plasma and liver triacylglyceride analysis. The plasma ALT and AST levels were measured using kits from Stanbio, and plasma HMGBl levels were measured using ELISA kits from antibodies-online (http://www.antibodies-online.com/). Liver triacylglyceride (TAG) was extracted and measured as previously described.

Histopathologic analysis and immunofluorescence microscopy. Formalin-fixed, paraffin-embedded mouse liver sections were stained with H&E to evaluate steatosis and inflammatory cell infiltration. Liver fibrosis was assessed by Picrosirius (sirius) red (Polysciences, catalog 24901) staining of the formalin-fixed, paraffin-embedded mouse liver sections. TUNEL staining was conducted on the cryosections of the livers using a kit from BioVision (K401-60). For immunofluorescence microscopy, cryosections of the livers were fixed with 10% formalin, blocked with 5% BSA (Sigma-Aldrich), and labeled with the antibody against mouse F4/80 (Abcam, ab16911) for 3 hours, followed by incubation with a fluorophore-conjugated secondary antibody (Thermo Fisher Scientific) for 1 hour. The stained sections were mounted with DAPI-containing mounting medium (VECTASHIELD) and then viewed on a Nikon A1-A fluorescence microscope. For parameters involving sirius red staining and F4/80 immunofluorescence, computerized image analysis (ImageJ, NIH) was used to quantify the area stained as a percentage of the total area of view. TUNEL· cells were quantified (Image J) in TUNEL staining liver section images as the percentage of total DAPI-stained cells. For lipid droplet number and size quantification, ImageJ was used on the H&E staining images. The same threshold settings were used for all analyses.

Measurement of collagen content of liver tissue. Collagen content in the livers was evaluated by measuring the hydroxyproline level in the livers using the Hydroxyproline Colorimetric Assay Kit (K555-100) from BioVision. Briefly, liver tissue was homogenized in water and samples were hydrolyzed by incubation with 6N hydrochloric acid at 120°C for 3 hours. Liver hydrolysates were oxidized using chloramine-T, followed by incubation with Ehrlich’s perchloric acid at 120°C for 3 hours. Liver hydrolysates were oxidized using chloramine-T, followed by incubation with Ehrlich’s perchloric acid reagent for color development. Absorbance was measured at 560 nm, and hydroxyproline quantities were calculated by reference to standards processed in parallel.

Ubiquitination assay. Hepa 1 cells were transfected with the plasmids encoding HA-tagged c-FLIPL, and Flag-tagged ubiquitin by using polyethyleneimine (Polysciences, catalog 23966). Ubiquitination assays were performed following a previously described protocol (46). Briefly, cells were lysed in 1% SDS buffer (Tris [pH 7.5], 0.5 mM EDTA, 1 mM DTT) and boiled for 10 minutes. For immunoprecipitation, the lysates were diluted 10-fold in Tris-HCl buffer. Ubiquitination was assayed using anti-Flag immunoblotting.

Flow cytometry analysis. For cell death analysis, primary hepatocytes and Hepa 1 cells were digested with 0.05% Trypsin-EDTA (Gibco, Thermo Fisher Scientific), washed with PBS, and then costained with annexin V/PI (V13242, Invitrogen) followed by flow cytometry. CD4+ T cell subpopulations in the liver were analyzed as described (47). Briefly, mouse livers were ground and lymphoid fraction in livers was isolated by density gradient centrifugation in Lymphoprep (AXS-1114547, Axis Shield) followed by in vitro stimulation with phorbol-miristate acetate (PMA) (100 ng/ml, Sigma-Aldrich) plus ionomycin (1 μM, Sigma-Aldrich) plus brefeldin A (1 μg/ml, Sigma-Aldrich) for 4 hours. Cells were first stained extracellularly with specific antibodies against mouse CD4, CD8, CD45, and CD90.2 (BD Biosciences), were then fixed and permeabilized with Fixation/Permeabilization Solution (eBioscience), and finally were stained intracellularly with antibodies against mouse IL-17, TNF-α, RORγt, and FOXP3 (BD Biosciences). Samples were acquired on a flow cytometry analyzer (LSR II; BD Biosciences), and data were analyzed with DIVA software (BD Biosciences).

Statistics. All results are presented as mean ± SEM. Student’s t test was used to analyze the differences between 2 groups, while 1-way ANOVA with post hoc Tukey’s test was used to evaluate differences among groups when 3 or more groups were analyzed. A P value of less than 0.05 was considered statistically significant. Statistical methods and corresponding P values for data shown in each panel are included in the figure legends. All representative experiments were repeated at least 3 times.

Study approval. All animal studies were approved by the Institutional Animal Care and Research Advisory Committee at the University of Michigan. The use of human liver samples was approved by the Institutional Review Board at Northeast Ohio Medical University (NEOMED).

Author contributions. JDL and LG conceived the project and designed research. LG, PZ, ZC, HX, and SL performed the experiments. SK provided NRG4 recombinant protein for in vitro studies. LG, HX, JDL, YZ, and WZ analyzed the data. LG and JDL wrote the manuscript.

Acknowledgments. We thank the NASH Clinical Research Network for sharing human liver tissue samples and the staff at the University of Michigan sequencing core for performing microarray analysis. This work was supported by the NIH (DK102456 and AG055379 to JDL and CA211016 to WZ), Novo Nordisk through a research agreement, the Michigan Diabetes Research Center (DK089503), and the Michigan Nutrition and Obesity Center (DK089503).

Address correspondence to: Jiandie Lin, 5437 Life Sciences Institute, University of Michigan, 210 Washtenaw Avenue, Ann Arbor, Michigan 48109, USA. Phone: 734.615.3512; Email: jdlin@umich.edu.
The Journal of Clinical Investigation


